- InterView
- "Lilly rises in anticancer and autoimmune diseases"
- by Eo, Yun-Ho Oct 27, 2022 05:52am
- The pharmaceutical company Lilly is known for their strong diabetes treatment pipeline. As the world’s first developer of insulin, Lilly has solidified its position in the field, introducing DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 analogues into its pipeline. However, Lilly has transformed. It did not give up diabetes, the company
- InterView
- “AstraZeneca’s sincerity in oncology drives cont. growth"
- by Eo, Yun-Ho Oct 17, 2022 06:03am
- AstraZeneca is known for its ‘sincere attitude’ towards R&D. Not only is the company in the top ranks in terms of its investment amount, but it has also always been at the forefront in terms of R&D-to-Total-revenue ratio as well. In 2021, AstraZeneca’s R&D-to-Total-revenue ratio stood at 26%, the highest in the industry. Due to their i
- InterView
- “Sanofi’s flu vaccine is different...has 100-year legacy"
- by Oct 6, 2022 06:05am
- Sanofi has been making unexpected strides in Korea's flu (influenza) vaccine market this year. The company has not only made a bid for the National Immunization Program (NIP) for the first time this year, but it also started supplying its flu vaccines exceptionally quickly. Multinational pharmaceutical companies usually start the supply of their
- InterView
- “Will rise independently as Organon in the industry”
- by Eo, Yun-Ho Sep 8, 2022 05:59am
- Spin-offs, which are made for various reasons in various circumstances, bring out various positive and negative issues in the process. Organon’s course of the spin-off was also quite eventful. However, the company quickly straightened its affairs after completing the spin-off and being reborn as an independent organization in June last y
- InterView
- "Leclaza’s mOS data of 38.9 months is remarkable"
- by Kim, Jin-Gu Jul 4, 2022 05:55am
- “The fact that Leclaza (lasertinib) achieved an OS (overall survival) of over 3 years is remarkable.” New OS data on the homegrown novel lung cancer drug Leclaza that was presented at the AOS 2022 & KCA Annual Meeting 2022 that was held recently in Seoul drew the pharmaceutical industry's attention. The results were from a trial that eva
- InterView
- Tremfya to bring generation shift in the IL inhibitor market
- by Jun 23, 2022 05:50am
- The competition among latecomers is intensifying in the interleukin inhibitor market with the scope of their indications expanding to psoriatic arthritis. The leader in this market is Janssen’s IL-12/23 inhibitor, ‘Stelara (Ustekinumab).’ Although 10 years have passed since its approval, the drug still boasts a growth rate in the 30% range
- InterView
- “Roche reborn through customer-centric reorganization”
- by Eo, Yun-Ho Jun 21, 2022 05:54am
- Multinational pharmaceutical companies are known to endlessly pursue change. In addition to active acquisitions, mergers, and spin-offs, the companies boldly reduce and expand their many originations in line with the new drug development trend, and show no hesitation in consolidating or reorganizing departments. Their endless evolution for e
- InterView
- Otrivin package made user-friendly for pharmacist & patient
- by Eo, Yun-Ho Jun 13, 2022 05:55am
- One strong perception of allergic rhinitis is that its symptoms worsen during the change of seasons and then decrease in summer. However, the large temperature difference between indoors and outdoors in summer due to excessive operation of air conditioners can dry out the mucous membranes and further weaken the immune system. Topical deco
- InterView
- “Allowing safe use of JAK inhibitors over restrictions"
- by Eo, Yun-Ho May 26, 2022 05:56am
- Nowadays, safety is as important as a drug’s efficacy. In particular, reaffirming the safety of drugs that require long-term administration post-approval is essential. JAK inhibitors, which have entered the market as an oral option to treat various autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis, have been em
- InterView
- We are making all efforts to reimburse ‘Vyndamax’
- by Eo, Yun-Ho Apr 21, 2022 06:03am
- Rare disease patients suffer more due to the 'rarity' of their condition. Due to the small number of affected patients, even drugs that are already available cannot be easily listed for reimbursement due to difficulty in demonstrating cost-effectiveness or predicting their fiscal impact on the NHI budget. Rare diseases are diseases that
